Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression

Zhang,Chuan; Huang,Yue; Long,Jiang; Yao,Xiaochen; Wang,Jun; Zang,Shimin; Qu,Wei; Wang,Feng

doi:10.3892/ol.2018.9795

Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression

Authors:
- Chuan Zhang
- Yue Huang
- Jiang Long
- Xiaochen Yao
- Jun Wang
- Shimin Zang
- Wei Qu
- Feng Wang
View Affiliations

Affiliations: Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China, Department of Pathology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, P.R. China, Department of Pancreas Surgery, Fudan University Shanghai Cancer Centre, Shanghai 200032, P.R. China
Published online on: December 5, 2018 https://doi.org/10.3892/ol.2018.9795
Pages: 1497-1504

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to assess the clinical value of serum chromogranin A (CgA) levels in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP‑NENs) and to compare them with tumour expression of CgA. A total of 109 consecutive patients with confirmed GEP‑NENs were enrolled in this prospective study between December 2012 and August 2016, including 73 patients with primary or recurrent GEP‑NENs and 36 patients with GEP‑NENs that were treated following surgery. Furthermore, 30 patients with benign gastrointestinal diseases and 30 healthy volunteers served as control groups. Serum CgA levels were measured by ELISA, using different reference values, in order to evaluate its diagnostic efficacy. Serum neuron‑specific enolase was also measured to evaluate its diagnostic efficacy and analyse its association with serum CgA levels. The levels of CgA, synaptophysin and neural cell adhesion molecule 1 in the tumour tissue were assessed by immunohistochemical assays. The results indicated that serum CgA levels were significantly higher in patients with GEP‑NENs compared with the control groups (P<0.05). No association was observed between serum CgA levels and tumour grade (G1, G2 and G3), but serum CgA levels differed significantly between patients with GEP‑NENs of different origins (P<0.05). A serum CgA cut‑off value of 85.3 ng/ml was associated with high sensitivity (64.4%) and specificity (92.7%). Different reference values were recommended for NENs of different origins, with serum CgA cut‑off values of 96.72, 51.13 and 86.19 ng/ml for the stomach, intestines and pancreas, respectively. The serum CgA levels were consistent with the CgA expression in the tumour. In conclusion, serum CgA may serve as a circulating pathological biomarker for the diagnosis of GEP‑NENs. The use of different reference values for different tumour origins may improve the diagnostic efficacy of CgA for GEP‑NENs. A cut‑off value of 85.3 ng/ml is recommended in the Chinese population.

View Figures

View References

1	Konecki DS, Benedum UM, Gerdes HH and Huttner WB: The primary structure of human chromogranin A and pancreastatin. J Biol Chem. 262:17026–17030. 1987.PubMed/NCBI
2	Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV and Kidd M: Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 17:2427–2443. 2010. View Article : Google Scholar : PubMed/NCBI
3	Påhlman S, Esscher T, Bergvall P and Odelstad L: Purification and characterization of human neuron-specific enolase: Radioimmunoassay development. Tumour Biol. 5:127–139. 1984.PubMed/NCBI
4	Baudin E, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin JC, Bidart JM, Cailleux AF, Bonacci R, Ruffié P and Schlumberger M: Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer. 78:1102–1107. 1998. View Article : Google Scholar : PubMed/NCBI
5	Fan JH, Zhang YQ, Shi SS, Chen YJ, Yuan XH, Jiang LM, Wang SM, Ma L, He YT, Feng CY, et al: A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocrine neoplasms in china. Oncotarget. 8:71699–71708. 2017.PubMed/NCBI
6	Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A and Evans DB: One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 26:3063–3072. 2008. View Article : Google Scholar : PubMed/NCBI
7	Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, et al: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 80:394–424. 2004. View Article : Google Scholar : PubMed/NCBI
8	McEntee GP, Nagorney DM, Kvols LK, Moertel CG and Grant CS: Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 108:1091–1096. 1990.PubMed/NCBI
9	Bosman FT, Carneiro F, Hruban RH and Theis ND: WHO classification of tumours of the digestive system. (4th). (Lyon). International Agency for Research on Cancer. 2010.PubMed/NCBI
10	Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm: China Consensus Guidelines for the standards of histopathologic diagnosis in Gastroenteropancreatic Neuroendocrine neoplasm. Chin J Pathol. 40:257–262. 2011.
11	Modlin IM, Lye KD and Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 97:934–959. 2003. View Article : Google Scholar : PubMed/NCBI
12	Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, et al: Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 16:e435–e446. 2015. View Article : Google Scholar : PubMed/NCBI
13	Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, Cherfi A and Öberg KE: Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 96:3741–3749. 2011. View Article : Google Scholar : PubMed/NCBI
14	Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Müller HH and Barth P: Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol. 6:820–827. 2008. View Article : Google Scholar : PubMed/NCBI
15	Jianming X, Houjie L, Shukui Q and Hui LW: Expert consensus on neuroendocrine tumors of the pancreas and stomach in China. J Clini Oncol. 21:927–946. 2016.
16	Jun E, Kim SC, Song KB, Hwang DW, Lee JH, Shin SH, Hong SM, Park KM and Lee YJ: Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: A prospective observational study from a single institute. Surgery. 162:120–130. 2017. View Article : Google Scholar : PubMed/NCBI
17	Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R and De Apollonia L: Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: Clinical role. Ann Oncol. 14:1135–1141. 2003. View Article : Google Scholar : PubMed/NCBI
18	Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, et al: The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 39:683–690. 2015. View Article : Google Scholar : PubMed/NCBI
19	Hijioka M, Ito T, Igarashi H, Fujimori N, Lee L, Nakamura T, Jensen RT and Takayanagi R: Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci. 105:1464–1471. 2014. View Article : Google Scholar : PubMed/NCBI
20	Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, et al: Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord. 14:642014. View Article : Google Scholar : PubMed/NCBI
21	Wang YH, Yang QC, Lin Y, Xue L, Chen MH and Chen J: Chromogranin A as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm. Medicine (Baltimore). 93:e2472014. View Article : Google Scholar : PubMed/NCBI
22	Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, et al: ENETS Consensus guidelines for the standards of care in neuroendocrine tumors: Towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 90:162–166. 2009. View Article : Google Scholar : PubMed/NCBI
23	Lai M, Lü B, Xing X, Xu E, Ren G and Huang Q: Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A. Virchows Arch. 449:402–409. 2006. View Article : Google Scholar : PubMed/NCBI
24	Xing X, Lai M, Gartner W, Xu E, Huang Q, Li H and Chen G: Identification of differentially expressed proteins in colorectal cancer by proteomics: Down-regulation of secretagogin. Proteomics. 6:2916–2923. 2006. View Article : Google Scholar : PubMed/NCBI
25	D'Alessandro M, Mariani P, Lomanto D, Carlei F, Lezoche E and Speranza V: Serum neuron-specific enolase in diagnosis and follow-up of gastrointestinal neuroendocrine tumors. Tumour Biol. 13:352–357. 1992. View Article : Google Scholar : PubMed/NCBI
26	Cunningham RT, Johnston CF, Irvine GB and Buchanan KD: Serum neurone-specific enolase levels in patients with neuroendocrine and carcinoid tumours. Clin Chim Acta. 212:123–131. 1992. View Article : Google Scholar : PubMed/NCBI
27	Oishi S and Sato T: Elevated serum neuron-specific enolase in patients with malignant pheochromocytoma. Cancer. 61:1167–1170. 1988. View Article : Google Scholar : PubMed/NCBI